ANDREW FERRETTI: Open Payments
NPI 1003193806 · ALLENTOWN, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,202 in 29 payments from 10 companies in 2025. Trend: 2023 $200 · 2024 $720 · 2025 $1,202
Food & beverage: $1,202
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 9 | $467 |
| Phathom Pharmaceuticals, Inc. | 2 | $146 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $142 |
| Optinose US, Inc. | 2 | $137 |
| GlaxoSmithKline, LLC. | 6 | $131 |
| Regeneron Healthcare Solutions, Inc. | 1 | $97 |
| Grifols USA, LLC | 1 | $24 |
| CSL Behring | 1 | $23 |
| Phadia US Inc. | 1 | $19 |
| AstraZeneca Pharmaceuticals LP | 1 | $16 |
Products named: DUPIXENT, VOQUEZNA, CUVITRU, Xhance, NUCALA, Xembify, Andembry, ImmunoCAP.
Industry payments across PA — which companies pay providers there.
